SCHEMBL7638993

SCHEMBL7638993

Cc1ccccc1CC(=O)C(=O)OCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.49
MAPK1 P28482 2/20 0.49
CTBP2 P56545 1/20 0.46
KMT2A Q03164 3/20 0.45
TDP1 Q9NUW8 2/20 0.45
SLC6A2 P23975 1/20 0.45
SLC6A3 Q01959 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.43
PTGER1 P34995 1/20 0.42
PTGER4 P35408 1/20 0.42
PTGER3 P43115 1/20 0.42
PTGER2 P43116 1/20 0.42
LMNA P02545 2/20 0.42
HCAR2 Q8TDS4 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7636904 0.85 KMT2A (0.49) ALDH1A1NPC1RAB9AL3MBTL1MAPK1
SCHEMBL7060854 0.85 PTGER4 (0.49) ALDH1A1NPC1RAB9AL3MBTL1MAPK1
SCHEMBL7643042 0.84 ALDH1A1 (0.49) ALDH1A1NPC1RAB9AL3MBTL1MAPK1
SCHEMBL10716907 0.84 ALDH1A1 (0.66) ALDH1A1NPC1RAB9AL3MBTL1MAPK1
SCHEMBL7637044 0.83 CTDSP1 (0.50) ALDH1A1CTBP2KMT2ALMNAKDM4E
SCHEMBL7640053 0.82 L3MBTL1 (0.56) ALDH1A1NPC1RAB9AL3MBTL1MAPK1
SCHEMBL7636977 0.81 ALDH1A1 (0.66) ALDH1A1L3MBTL1MAPK1KMT2ATDP1
SCHEMBL7633415 0.81 ALDH1A1 (0.49) ALDH1A1L3MBTL1MAPK1KMT2ATDP1
SCHEMBL7634852 0.81 ALDH1A1 (0.50) ALDH1A1RAB9AL3MBTL1MAPK1CTBP2
SCHEMBL7641604 0.81 ALDH1A1 (0.49) ALDH1A1NPC1L3MBTL1MAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2594563-B1 2-acylaminopropanol-type glucosylceramide synthase inhibitors GENZYME CORP (US) 2018-07-18 EP disclosed
WO-2018118711-A1 SMALL MOLECULE FERROPTOSIS INDUCERS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2018-06-28 WO disclosed
US-20180093981-A1 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors GENZYME CORPORATION 2018-04-05 US disclosed
US-20180093981-A1 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors GENZYME CORPORATION 2018-04-05 US disclosed
US-6348617-B1 REACTING PYRUVIC ACID COMPOUND IN WATER WITH AMMONIUM OR ALKALI METAL BISULFITE TO GIVE AQUEOUS SOLUTION OF BISULFITE ADDUCT, ISOLATING BY PHASE SEPARATION, OPTIONALLY USING HYDROPHOBIC SOLVENT, CONTACTING WITH ACID TO DECOMPOSE ADDUCT SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-02-19 US disclosed
EP-0937703-A1 METHOD FOR PURIFYING PYRUVIC ACID COMPOUNDS SUMITOMO CHEMICAL COMPANY LIMITED (JP) 1999-08-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180093981-A1 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors ASAH2, GBA1, GAA ALDH1A1 961/4885NPC1 254/4885RAB9A 2280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.